On February 28, 2025, Interpace Biosciences announced it will restate its financial statements for 2023 and several quarters in 2024 due to overstatement of accrued royalties, affecting liabilities by approximately $6.0 million for 2023 and smaller amounts for each quarter in 2024. Investors should not rely on the previously issued financial statements as they will be amended to reflect these changes.